Related Experiment Videos
Cyclosporine-associated renal arteriopathy resulting in loss of allograft function
Insights
Cyclosporine-associated arteriopathy caused 40% of graft loss in renal transplants. This condition, marked by vascular damage and thrombosis, led to irreversible graft failure in most patients.
Area of Science:
- Nephrology
- Transplantation Immunology
- Vascular Biology
Background:
- Cyclosporine is a crucial immunosuppressant in renal transplantation.
- Cyclosporine-associated arteriopathy (CAA) is a significant cause of allograft failure.
- Understanding CAA's pathogenesis is vital for improving transplant outcomes.
Purpose of the Study:
- To investigate the incidence and characteristics of cyclosporine-associated arteriopathy in cadaveric renal allografts.
- To differentiate CAA from acute rejection based on clinical and pathological findings.
- To explore potential therapeutic interventions for CAA.
Main Methods:
- Analysis of 200 consecutive cadaveric renal transplants with graft loss.
- Diagnosis of arteriopathy via biopsy and indium 111m labeled platelet uptake.
- Histopathological examination of allograft biopsies, including immunofluorescence.
- Clinical assessment of patient presentation and response to treatment.
Main Results:
- Cyclosporine-associated arteriopathy was responsible for 40% of allograft failures.
- Histopathology revealed fibrin deposition, intimal proliferation, and arterial thrombosis, distinct from acute rejection.
- Two clinical patterns emerged: rapid anuria (Group I) and gradual renal function decline (Group II).
- One patient recovered function after streptokinase and heparin treatment.
Conclusions:
- Cyclosporine-associated arteriopathy is a major cause of renal allograft loss.
- CAA presents with distinct vascular pathology and is not indicative of acute rejection.
- Reduced prostacyclin may contribute to the development of CAA, suggesting potential therapeutic targets.
Abstract:
Cyclosporine-associated arteriopathy was the cause of graft loss in 40 percent of all allografts that failed in a series of 200 consecutive cadaveric renal transplants. Arteriopathy was diagnosed by biopsy and renal uptake of indium 111m labeled platelets in the face of acute renal deterioration. A moderate thrombocytopenia and microangiopathic picture of hemolytic uremia was also present on peripheral blood smear. Immunofluorescence and histologic characteristics of the allograft biopsy specimens failed to show evidence for acute rejection: immunoglobulin M, immunoglobulin A, immunoglobulin G, C1q, C3, and C4 were not present, and there was no evidence of an interstitial or vascular mononuclear cellular infiltrate. Two clinical presentations have been described. In Group I (seven patients), anuria occurred rapidly within the first 2 weeks after transplantation. In Group II (nine patients) renal function gradually diminished 1 to 5 months after starting cyclosporine therapy. Fifteen of the 16 recipients had progressive and irreversible loss of renal function which was pathologically associated with fibrin deposition, intimal proliferation, and thrombotic occlusion of the cortical interlobular and arcuate arteries, with subsequent focal glomerular ischemia and cortical infarction. One recipient with rapid loss of renal function received an intraarterial allograft infusion of streptokinase and subsequent systemic heparinization, which resulted in return of normal allograft function. The syndrome of cyclosporine-associated arteriopathy has been linked to a lack of or reduced amounts of prostacyclin-stimulating factor or prostacyclin.